News Patient sues Novartis, claiming data-tracking privacy breach A cancer patient in the US has filed a class action lawsuit against Novartis in the US, claiming that the company shared her private health data.
News ESMO: Lilly reveals scale of survival win with Verzenio Eli Lilly has revealed long-term follow-up data with adjuvant Verzenio in early breast cancer, including a 15.8% improvement in survival.
News Lilly raises stakes in Novartis battle with Verzenio data Armed with new survival data for Verzenio in early breast cancer, Lilly hopes to keep the drug's nose in front of a fast-growing rival from Novartis.
News NICE relents and backs Kisqali for wide use in breast cancer Novartis' breast cancer therapy Kisqali has been cleared for NHS use in early breast cancer, an indication driving blockbuster sales of the drug.
News Kisqali gets early breast cancer approval in Europe Novartis' fast-growing breast cancer drug gets another growth driver as EU approves adjuvant use in patients with early-stage HR+, HER2- tumours
News Lilly on alert as new Kisqali approval threatens Verzenio Novartis' CDK4/6 inhibitor Kisqali has claimed a broad FDA approval in early breast cancer that could give it an edge over class rival Verzenio from Eli Lilly.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.